Compare Johnson & Johnson (JNJ) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs The Coca-Cola Co K — how do they compare? Johnson & Johnson trades at $259 (market cap $618.09B), while The Coca-Cola Co K trades at $87.98 (market cap $377.63B). The key difference: Johnson & Johnson is the larger of the two by market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and The Coca-Cola Co K for 154 Days on average.
| JNJ | KO | |
|---|---|---|
Market Cap | $618.09B | $377.63B |
Volume | 6,050,983 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $91.99 |
52-Week Low | $186.00 | $66.37 |
Typical Hold Time | 129 Days | 154 Days |
Enterprise Value | $646.37B | $404.81B |
Dividend Yield | 2.09% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $0.97 beating expectations of $0.92. Revenue growth remains steady at $47.94B for 2025, with net income margin improving to 28.56%. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential from current levels.
The stock presents a compelling dividend opportunity with 64 consecutive years of dividend increases, though technical weakness and regional demand divergence pose near-term risks. Long-term investors may find value in the company's stable cash flows and global brand strength, while short-term traders should monitor support at $85 for potential entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
